SHIKARI® (QS-INFLIXI)

This kit has been especially developed for the specific and quantitative determination of free Infliximab (Remicade®, Remsima®) in serum and plasma samples between the Cmin and Cmax range of concentrations.
All SHIKARI® ELISA kits are suitable for biosimilar work. All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

Please contact us at for specific academic pricing.

Background

Infliximab Drug Bank Accession Number is DB00065.
Infliximab is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease and ankylosing spondylitis. Infliximab binds with high affinity to soluble and transmembrane forms of TNF-α to disrupt the proinflammatory cascade signaling. Binding of antibodies to TNF-a prevents TNF-a from interacting with its receptors and helps the patient recover. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

More Details